Psychedelic Therapy Legal Status 2026: Country-by-Country Guide

The regulatory landscape for psychedelic-assisted therapy is undergoing its most rapid transformation in decades. Since Australia's landmark 2023 rescheduling of psilocybin and MDMA, multiple jurisdictions have followed with their own regulatory innovations. In 2026, clinicians, patients, and investors face a complex, rapidly changing patchwork of rules.

Australia: The World's First National Approval

Australia became the first country to reclassify psilocybin and MDMA as Schedule 8 (controlled but prescribable) substances in February 2023, effective July 2023. Authorized Prescribers—psychiatrists who complete a training programme—can now legally prescribe:

Early clinical data from licensed Australian practitioners is consistent with trial findings, though access remains limited by the small number of trained providers and high treatment costs (estimates range from AUD 15,000–25,000 per course).

Oregon: Regulated Service Centres

Oregon's Measure 109 (2020) created a unique model: rather than medical prescription, it established a regulated wellness framework where trained facilitators administer psilocybin in licensed service centres without requiring a psychiatric diagnosis. By Q1 2026, Oregon has licensed approximately 354 facilitators and dozens of service centres statewide.

The Oregon model is being watched globally as a potential template for non-medical access. Preliminary data from the Oregon Psilocybin Advisory Board suggests positive outcomes, though formal outcome tracking infrastructure is still being developed.

Switzerland: Compassionate Access Since 2014

Switzerland has permitted psilocybin therapy under exceptional-use (Ausnahmebewilligung) provisions since 2014. The Swiss Federal Office of Public Health (BAG/OFSP) grants individual permits for patients with life-threatening conditions or severe treatment-resistant disorders. An expanded access programme, partially informed by Peter Gasser's seminal LSD anxiety work, has allowed hundreds of Swiss patients to access therapy.

Canada and the United States

Canada's Section 56 exemption programme allows individual patients to apply for psilocybin therapy; Health Canada has granted hundreds of exemptions since 2020, primarily for end-of-life anxiety and depression.

In the United States, despite the FDA's 2024 deferral of MDMA approval, psilocybin retains Breakthrough Therapy designation for MDD and TRD. Multiple Phase 3 trials are ongoing, and state-level initiatives in Colorado, California, and New York are creating pathways for regulated access.

Explore more: Browse clinical trials · Substance profiles · All studies

References